K2M reported strong financial performance in the second quarter of 2016, ended June 30.
Here are 10 key notes:
1. The company's total reported revenue was $59.2 million for the second quarter of 2016, up 5.1 percent compared to the same period the year prior.
2. Total revenue increased 5.3 percent year-over-year on a constant currency basis.
3. K2M suffered a net loss of $11.1 million in the second quarter, as compared to a loss of $6.2 million during the same period last year.
4. Revenue in the United States increased 9.2 percent from the second quarter in 2015 to $45.2 million.
5. U.S. revenue for K2M's complex spine category grew 8.2 percent; minimally invasive surgery category grew 15.9 percent and degenerative category grew 7.9 percent.
6. International revenue decreased $0.9 million to $14 million in the second quarter of this year.
7. Operating expenses for second quarter 2016 increased by 5.5 percent from the same period last year to $48.9 million.
8. Loss from operations for the second quarter was $9.3 million, compared to an $8.6 million loss from operations last in the second quarter of 2015.
9. Gross profit for second quarter of 2016 increased to $39.6 million, compared to $37.7 million for second quarter of 2015.
10. The company received FDA clearance for a number of products in the second quarter, including the CASCADIA Cervical and the CASCADIA AN Lordotic Oblique Interbody Systems.